← All trials
NCT06303128
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 3, 2024
- Primary completion
- Dec 31, 2024
- Completion date
- May 31, 2025
- First posted
- Mar 12, 2024
- Last posted
- Mar 15, 2024
- Enrollment
- 380
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Texas Tech UniversityLead sponsor
- Texas Tech UniversitySponsor investigator
- Texas Tech UniversityOfficial
- Texas Tech UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.